CD40 and Hodgkins lymphoma: A phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in 50 patients with refractory or recurrent non-HL has been performed showing an acceptable safety profile and modest activity with 6 objective responses reported [244].